Abstract
Several trials have shown the superior impact of high-dose melphalan (usually 200mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum β2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P
| Original language | English |
|---|---|
| Pages (from-to) | 133-138 |
| Number of pages | 6 |
| Journal | Leukemia |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2004 |
Fingerprint
Keywords
- Dose-intensive
- Melphalan
- Myelomatransplantation
ASJC Scopus subject areas
- Hematology
- Cancer Research
Cite this
Multiple myeloma : Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2). / Palumbo, A.; Bringhen, S.; Bertola, A.; Cavallo, F.; Falco, P.; Massaia, M.; Bruno, B.; Rus, C.; Barbui, A.; Caravita, T.; Musto, P.; Pescota, N.; Rossini, F.; Vignetti, M.; Boccadoro, Mario.
In: Leukemia, Vol. 18, No. 1, 01.2004, p. 133-138.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multiple myeloma
T2 - Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)
AU - Palumbo, A.
AU - Bringhen, S.
AU - Bertola, A.
AU - Cavallo, F.
AU - Falco, P.
AU - Massaia, M.
AU - Bruno, B.
AU - Rus, C.
AU - Barbui, A.
AU - Caravita, T.
AU - Musto, P.
AU - Pescota, N.
AU - Rossini, F.
AU - Vignetti, M.
AU - Boccadoro, Mario
PY - 2004/1
Y1 - 2004/1
N2 - Several trials have shown the superior impact of high-dose melphalan (usually 200mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum β2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P
AB - Several trials have shown the superior impact of high-dose melphalan (usually 200mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum β2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P
KW - Dose-intensive
KW - Melphalan
KW - Myelomatransplantation
UR - http://www.scopus.com/inward/record.url?scp=10744225243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744225243&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2403196
DO - 10.1038/sj.leu.2403196
M3 - Article
C2 - 14586481
AN - SCOPUS:10744225243
VL - 18
SP - 133
EP - 138
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 1
ER -